Download - Heart Failure Society of America

How-To 

Hands-On 

Team-Based 

New Technologies 

17th Annual Scientific Meeting 

Advance Program & 

Registration Information 

September 22 – 25, 2013 

The Peabody Orlando Hotel 

Orlando, Florida 

www.hfsa.org

advance program 


Executive Council 

About HFSA 

2013 Meeting Highlights 

General Information 

Officers 

Thomas Force, MD (President) 

JoAnn Lindenfeld, MD (Vice-President) 

Mariann Piano, RN, PhD (Secretary) 

Christopher M. O’Connor, MD (Treasurer) 

Barry M. Massie, MD (Immediate Past-President) 

Members 

Nancy M. Albert, RN, PhD 

John C. Burnett, MD 

Javed Butler, MD, MPH 

John Chin, MD 

Joseph A. Hill, MD, PhD 

Steven R. Houser, PhD 

Sharon A. Hunt, MD 

Corrine Y. Jurgens, RN, PhD 

Sara C. Paul, DNP, FNP 

Heather J. Ross, MD 

Randall C. Starling, MD, MPH 

James E. Udelson, MD 

Michael R. Zile, MD 

Members (ex officio) 

Jay N. Cohn, MD 

Gary S. Francis, MD 

David A. Lathrop, PhD 

2013 Scientific Program Committee 

David DeNofrio, MD (Co-Chair) 

Jeffery D. Molkentin, PhD (Co-Chair) 

Robin J. Trupp, RN, PhD, APRN-BC (Co-Chair) 

Burns C. Blaxall, PhD 

Biykem Bozkurt, MD 

Harleah G. Buck, RN, PhD, CHPN 

Thomas P. Cappola, MD, ScM 

Mark H. Drazner, MD 

Anecita Fadol, PhD, FNP-BC 

James C. Fang, MD 

G. Michael Felker, MD 

Daniel E. Forman, MD 

Jalal K. Ghali, MD 

Joshua I. Goldhaber, MD 

Asa B. Gustafsson, PhD 

Stuart D. Katz, MD 

Maria I. Kontaridis, PhD 

Ann S. Laramee, APRN 

Christopher Lee, RN, PhD 

Wayne C. Levy, MD 

W. Robb MacLellan, MD 

Linda J. Ordway, RN, MSN, ACNPc 

Robert Lee Page II, PharmD, MSPH 

Michael G. Petty, RN, CCNS, ACNS 

Margaret M. Redfield, MD 

Paul B. Rosenberg, MD 

Douglas B. Sawyer, MD, PhD 

Jagmeet P. Singh, MD, PhD 

Mary N. Walsh, MD 

Yibin Wang, PhD 

Steven R. Houser, PhD (ad-hoc) 

Barbara J. Riegel, DNSc, FANN, FAHA (ad-hoc) 

Lynne Warner Stevenson, MD (ad-hoc) 

The Heart Failure Society of America (HFSA) represents the first organized effort by 

heart failure experts from the Americas to provide a forum for all those interested in 

heart failure research and patient care. 

The HFSA is dedicated to: 

❚❚ 

Promoting research related to all aspects of heart failure and to providing a forum 

for presentation of basic, clinical and population-based research. 

❚❚ 

Educating health care professionals through programs, publications, and other 

media in the areas of basic science, clinical medicine, patient management, and 

social, ethical and economic issues to enable them to diagnose and treat heart 

failure and concomitant medical conditions more effectively.. 

❚❚ 

Encouraging primary and secondary preventive measures to reduce the incidence 

of heart failure; serving as a resource for government, private industry, and health 

care providers to facilitate the establishment of programs and policies that will 

better serve the patient. 

❚❚ 

Enhancing quality and duration of life in those with heart failure. 

❚❚ 

Promoting and facilitating the formal training of physicians, scientists and allied 

health care providers in the field of heart failure. 

Membership Information 

Membership in the Society is open to all health care professionals with an interest 

in cardiovascular medicine. For information about the HFSA and how to become a 

member, visit the HFSA web site: www.hfsa.org. 

Note: To take advantage of the advanced membership registration rate for the 17th 

Annual Scientific Meeting individuals must have paid 2013 dues and be a member in 

good standing by July 30, 2013.. 

For questions, contact: 

Heart Failure Society of America (HFSA) 

5425 Wisconsin Avenue, Suite 600 

Chevy Chase, MD 20815 

Phone: (301) 718-4800 

Fax: (301) 968-2369 

Email: info@hfsa.org 

Web site: www.hfsa.org 

The 2013 meeting starts off with a full Sunday program, including the Excellence in 

Basic Science session, the ICCAC-VAD session, a special Myocarditis Symposium, 

a joint symposium with AHA on Heart Failure Prevention, and the first of three 

installments of Clinical Fundamentals, continuing a very successful program started 

two years ago. 

Monday kicks off with a plenary session featuring three national speakers on Health 

Care Reform and continues with a full schedule of scientific sessions, How-to 

Sessions, Rapid-Fire Sessions, and posters. 

Tuesday and Wednesday includes joint sessions with HRS, the European and 

Japanese Heart Failure Societies, the Industry Session, Hyde Park, Debates, Case 

Studies, and more. And that’s not counting the satellite symposia and activities in the 

exhibit hall, including product theaters and hands-on workshops. All in the wonderful 

Peabody Hotel. 

Exhibitors 

There is no identified exhibitor block at the HFSA Annual Scientific Meeting. 

Companies/groups wanting to reserve a block of rooms should contact 

Gudrun Echterhoff at gudrun@global-mtgs.com 

(201-850-7607 / 201-766-5044) for details. 

The 17th Annual Scientific Meeting of the Heart Failure Society of America offers a 

diverse program including basic science, translational and clinical sessions. There is 

something for everyone interested in heart failure. 

Typical Attendees Expected 

It is anticipated that attendees will include 

HFSA members: 

❚❚ 

Cardiologists, CV surgeons, internists and primary care physicians 

❚❚ 

Clinical researchers 

❚❚ 

Cardiac rehabilitation professionals 

❚❚ 

Nurses, Nurse Practitioners 

❚❚ 

Epidemiologists 

❚❚ 

Health care administrators 

❚❚ 

Industry 

❚❚ 

Pharmacists 

❚❚ 

Research scientists 

Visas / Letters of Invitation 

Letters of invitation for visa purposes will be provided by the HFSA office upon 

request. Please email your request to info@hfsa.org. It should be understood that the 

letter of invitation is meant to help members obtain a visa and is not a commitment 

on the part of the organizers to provide any financial support. The decision to grant 

a visa belongs solely to the embassy/consulate. Should your application be denied, 

HFSA cannot change the decision of the government agency. 

Special Needs 

The HFSA strives to hold meetings that are accessible to all. Please tell us what 

you require to help make your participation more enjoyable and meaningful. 

Contact Gudrun Echterhoff at gudrun@global-mtgs.com (201-850-7607 / 201- 

766-5044). 

Liability Statement 

Disclaimer: The Heart Failure Society of America 

(HFSA) cannot accept, and hereby specifically 

disclaims, any liability for death, injury, any loss, 

cost or expense suffered or incurred by any person 

if such loss is caused by, arises from or results from 

the act, default or omission of any person other 

than an employee or agent of HFSA. In particular, 

neither HFSA nor its agents can accept, and hereby 

specifically disclaims, any liability for losses arising 

from, caused by, or resulting from, the provision or 

non-provision of services provided by the hotels, 

companies, or transport operators. Neither HFSA 

nor its agents can accept, and hereby specifically 

disclaims, liability for losses suffered by reason of 

war including threat of war, riots and civil strife, 

terrorist activity, natural disaster, weather, fire, flood, drought, technical, mechanical 

or electrical breakdown within any premises visited by delegates and/or participants 

in connection with the meeting, industrial disputes, government action, regulations 

or technical problems that affect or may affect the services provided in connection 

with the meeting. HFSA is not able to warrant and does not warrant that a particular 

person will appear as a speaker. As a condition to any participation in or attendance at 

the Annual Scientific Meeting or any function associated or affiliated herewith, each 

attendee and participant accepts the foregoing disclaimer. 

2 

3


ORLANDO: A DESTINATION 

The Peabody Orlando 

9801 International dr, orlando, FL 

City Walk at Universal Studios 

Attractions, Arts & Culture, Shopping 

Orlando is the premier destination to make all of your vacation dreams come true, 

known for its world-famous theme parks, attractions, performing and visual arts. 

Once a quiet farming town, Orlando has become one of the world’s fastest-growing 

cities and the most popular family destination on earth. It is among Florida’s major 

cities and is a center for digital media and bio medicine. Today Orlando has the 9th 

busiest airport in the U.S. and is warm and sunny all year round. 

Restaurants 

Orlando has evolved into a popular culinary destination with sophisticated restaurant 

options for every taste. From independently owned neighborhood restaurants to 

family-friendly establishments, the Orlando area offers a surprisingly diverse array of 

epicurean delights. Visitors with sophisticated palates will find a number of celebrity 

chef-anchored, four- and five-diamond restaurants, and wine connoisseurs can take 

advantage of the city’s multiple certified master sommeliers. 

Disney World 

Conference Location 

Sea World 

The 17th Annual Scientific Meeting of the HFSA will be held at the Peabody Hotel 

in Orlando, Florida. The Peabody Hotel is central to Orlando’s world-famous theme 

parks, attractions, performing and visual arts; it is the ultimate address to explore 

the city. The Peabody resides five minutes from Universal Orlando Resort and Sea 

World, and 15 minutes from Disney World and downtown Orlando’s performing and 

visual arts, featuring the Orlando Ballet, Orlando Opera Company, UCF Shakespeare 

Festival, and Charles Hosmer Morse Museum of American Art in Winter Park. The 

Mall at Millenia, the Florida Mall and Festival Bay abound with exclusive shops and 

boutiques. 

O R L A N D O 

Exhibitor Dates and Hours 

Install 

Saturday September 21 9:00 AM - 5:00 PM 

Sunday September 22 7:00 AM - 3:00 PM 

On-Site Registration Opens 

Saturday September 21 9:00 AM - 4:00 PM 

Explore the variety of cultural 

attractions and unique history of 

Central Florida and make sure to 

take in a performance of Orlando 

Ballet, Orlando Opera Company, 

UCF Shakespeare Festival, or 

visit Lakeridge – Florida’s largest 

premium winery. The excitement 

doesn’t stop there with all-season 

golf courses and t world renowned 

sunny beaches. Less known but 

equally inviting are the downtown 

sections of Orlando itself and many 

nearby towns in Central Florida. 

Climate & Dress 

The average high temperature in September is 90○ F and the average low is 72○ F. 

On any given day it can be hot enough for a day at the beach, or cool enough for a 

light-weight jacket. Business casual attire is appropriate for all meeting and social 

events. 

Universal CityWalk 

Known as the Entertainment Capital 

of Orlando, Universal CityWalk is the 

neighborhood of variety. Relax over 

dinner, mingle over cocktails, see a wild 

concert, catch the latest movie or even 

dance the night away. You can do it all 

in one night and in one place – Universal 

CityWalk, Orlando’s hottest spot for 

entertainment. 

As popular with locals as it is with 

visitors, this 30-acre entertainment 

complex is Orlando’s ideal destination 

for a night of family fun, a place to hang 

out with friends, or a romantic evening for couples. In addition to its nightclubs, 

restaurants, shops and cinemas, Universal CityWalk is also host to a variety of 

concerts and special events throughout the year. 

Register Online 

Exhibit Hours 

Sunday September 22 6:00 PM – 8:00 PM 

Registration for the 17th Annual Scientific Meeting is available online at Hfsa.org. If 

you do not wish to register online, you may fill out the form on page 28 of this brochure 

and return the form by mail with payment to: HFSA, 5425 Wisconsin Ave., Suite 600, 

Chevy Chase, MD 20815. 

Registration Fee 

Monday September 23 10:00 AM – 6:00 PM 

Tuesday September 24 10:00 AM – 6:00 PM 

An application to exhibit and exhibit prospectus may be obtained by contacting the 

HFSA at info@hfsa.org, (301) 718-4800 or fax: (301) 968-2369 or download a copy at 

hfsa.org (annual scientific meeting). 

The registration fee includes admittance to all meeting events, including scientific 

sessions, opening reception, poster sessions, satellite symposia, and commercial 

exhibits. 

History 

Prior to the arrival of the first European settlers in 1837, the area 

that is now Orlando was occupied by the Seminole tribe of Native 

Americans. The “Town of Orlando” was incorporated on July 31, 

1875 with an area of 4 square miles. The development of Walt 

Disney World in 1971 spurred a construction boom that included 

apartment buildings, hotels, banks, commercial shopping areas, 

and tourist-related businesses. Today, the City of Orlando as a 

result of numerous annexations has an area of over 100 square 

miles and is still located entirely within Orange County. Tourism 

is still the city’s primary industry, but Orlando has also developed 

a reputation for high tech businesses and industries both related 

and unrelated to the entertainment industry. 

4 

5


advance program: Confirmed Faculty 

CME Information 

Scientific Program 

Keith Aaronson, MD 

Ann Arbor, MI 

Barry A. Borlaug, MD 

Rochester, MN 

Frederica del Monte, MD, PhD 

Boston, MA 

Mona Fiuzat, PharmD 

Durham, NC 

2013 Learning Objectives 

Following this meeting, participants will be able to: 

❚❚ 

Describe the epidemiology of HF and implement strategies for the prevention of 

HF. 

❚❚ 

Describe current knowledge about the scientific basis of HF from the perspectives 

of cardiovascular physiology, neurohormones, tissue factors, molecular biology, 

and genetics. 

❚❚ 

Identify the findings of basic science research and current clinical trials and 

describe their implications for current and future HF therapy. 

❚❚ 

Implement optimal guideline-based therapeutic options for HF, including 

pharmacologic agents, non-pharmacologic options, such as diet and exercise; and 

implantable devices. 

❚❚ 

Manage comorbidities including hypertension, diabetes, depression, sleep apnea, 

and chemotherapy. 

❚❚ 

Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues 

in the treatment of patients with HF. 

❚❚ 

Implement strategies for effective management of the patient with HF, 

incorporating the family, encouraging self-care, and employing the team approach. 

❚❚ 

Outline strategies for transitioning patients from impatient to outpatient care and 

for reducing hospital readmissions.s 

❚❚ 

Engage in performance measurement and other site-based research 

❚❚ 

Outline strategies for more effective communication with patients, families, and 

other health professionals. 

Poster Sessions 

Poster sessions provide opportunity for interaction between the presenter and the 

audience. Posters will be on display Monday and Tuesday from 9:30am to 6:00pm. 

Presenters will be at their posters on Monday and Tuesday from 12:30pm to 

1:30pm. 

Satellite Symposia 

Satellite symposia will offer 1 hour, 1 ½ hours or 2 hours of credit depending on the 

satellite. Badges will be scanned by staff when entering a session (including satellite 

programs). This information will be used to identify attendance for CME credits and 

used exclusively by the HFSA. No information will be sold or shared with anyone 

outside the HFSA. 

Physicians 

The Heart Failure Society of America is accredited by the Accreditation Council for 

Continuing Medical Education to provide continuing medical education for physicians. 

The Heart Failure Society of America designates this live activity for a maximum 

of 25 AMA PRA Category 1 Credits. Physicians should claim only the credit 

commensurate with the extent of their participation in the activity. 

Nurses 

This program has been approved by the American Association of Critical Care 

Nurses (AACN) for 25.1 Contact Hours, Synergy CERP Category A, File number 

00018433. 

Pharmacists 

The CU Skaggs School of Pharmacy and Pharmaceutical 

Sciences is accredited by the Accreditation Council for Pharmacy 

Education as a provider of continuing pharmacy education. This 

program has been accredited for up to 18.75 contact hours. To 

receive CE credit for this seminar, participants must complete 

all evaluations for programs attended and provide their NABP 

eProfile ID number and month and day of their birthdate. CE credit will be 

uploaded to CPE monitor within 60 days. 

❚❚ 

Clinical Fundamentals I: Management of Acute Heart Failure, 

0008-9999-13-054-L01-P 

❚❚ 

The Prevention of Heart Failure, 0008-9999-13-055-L01-P 

❚❚ 

Treatment of Heart Failure with Preserved Ejection Fraction, 

0008-9999-13-056-L01-P 

❚❚ 

The Impact of Health Care Reform, 0008-9999-13-057-L01-P 

❚❚ 

Heart Failure Trials: The Year in Review, 0008-9999-13-058-L01-P 

❚❚ 

Heart Failure Readmissions: Appropriate Focus or Misguided Efforts? 

0008-9999-13-059-L01-P 

❚❚ 

Heart Failure in the Frail Elderly: Perils and Pitfalls, 0008-9999-13-063-L01-P 

❚❚ 

Alternative and OTC Medicine Conundrum - Considerations in HF, 

0008-9999-13-064-L01-P 

❚❚ 

Acute Heart Failure: Role of Pre-Hospital Care and the ED, 

0008-9999-13-066-L01-P 

William T. Abraham, MD 

Columbus, OH 

Michael Acker, MD 

Philadelphia, PA 

Kirkwood Adams, MD 

Chapel Hill, NC 

Philip Adamson, MD 

Oklahoma City, OK 

Nancy Albert, PhD, CNS 

Cleveland, OH 

Larry Allen, MD 

Denver, CO 

Inder Anand, MD 

Minneapolis, MN 

Ada Andrade, ANP 

Toronto, ON, Canada 

Shauna Andrus, RN 

Seattle, WA 

Stefan Anker, MD 

Berlin, Germany 

Christopher P. Baines, PhD 

Columbia, MO 

Jose Banchs, MD 

Houston, TX 

Vimy Barnard-Roberts, ANP 


Susan Barnason, PhD, RN 

Lincoln, NE 

Biykem Bozkurt, MD 

Houston, TX 

Michael Bristow, MD 

Aurora, CO 

John Burnett Jr., MD 

Rochester, MN 

Javed Butler, MD 

Atlanta, GA 

Daniela Cardinale, MD, PhD 

Milan, Italy 

Peter Carson, MD 

Washington, DC 

Michael Chernew, PhD 

Boston, MA 

Suzanne Chillcott, BSN, RN 

San Diego, CA 

John Chin, MD 

Sacramento, CA 

Sheryl Chow, PharmD 

Los Angeles, CA 

Eugene Chung, MD 

Cincinnati, OH 

Jay N. Cohn, MD 


Sean Collins, MD 

Nashville, TN 

Monica Colvin-Adams, MD, MS 


David DeNofrio, MD 

Boston, MA 

Michael Dickinson, MD 

Grand Rapids, MI 

Vasken Dilsizian, MD 

Baltimore, MD 

Gerald W. Dorn, MD 

St. Louis, MO 

Mark Drazner, MD 

Dallas, TX 

Zubin Eapen, MD 

Durham, NC 

Uri Elkayam, MD 


Tonya Elliott, MSN, RN 

Fairfax, VA 

Howard Eisen, MD 


NA Mark Estes III, MD 

Boston, MA 

Gregory Ewald, MD 

St. Louis, MO 

Anecita P. Fadol, NP 

Houston, TX 

DeLisa Fairweather, PhD 

Baltimore, MD 

James Fang, MD 

Cleveland, OH 

Gregg Fonarow, MD 


Thomas L. Force, MD 


Daniel E. Forman, MD 

Boston, MA 

Nikolaos Frangogiannis, MD 

Bronx, NY 

Daniel J. Garry, MD 


Jalal Ghali, MD 

Detroit, MI 

Mihai Gheorghiade, MD 

Chicago, IL 

Mahazarin B. Ginwalla, MD 

Cleveland, OH 

Michael Givertz, MD 

Boston, MA 

Lee R. Goldberg, MD, MPH 


Stephen Gottlieb, MD 

Baltimore, MD 

Kathy L. Grady, PhD, APN 

Chicago, IL 

Barry H. Greenberg, MD 

San Diego, CA 

Asa Gustafsson, PhD 

San Diego, CA 

❚❚ 

Quality of Care Issues in Left Ventricular Assist Devices, 

0008-9999-13-067-L01-P 

Bradley A. Bart, MD 


Leslie T. Cooper, MD 

Rochester, MN 

Steven Farmer, MD, PhD 

Chicago, IL 

Shelley Hall, MD 

Dallas, TX 

❚❚ 

The Pregnant Patient with Heart Failure, 0008-9999-13-068-L01-P 

❚❚ 

Pulmonary Hypertension in Heart Failure, 0008-9999-13-069-L01-P 

David J. Beech, BSc, PhD 

Leeds, United Kingdom 

Maria Rosa Costanzo, MD 

Naperville, IL 

David S. Feldman, MD, PhD 


Joshua M. Hare, MD 

Miami, FL 

Cynthia Bither, MSN, ANP 

Washington, DC 

Madeleine W. Cunningham, PhD 


G. Michael Felker, MD 

Durham, NC 

Paul Hauptman, MD 

St. Louis, MO 

Lori Blauwet, MD 

Rochester, MN 

Anne B. Curtis, MD 

Buffalo, NY 

Gregory J. Fermann, MD 


Andrew Hawarth 

Calgary, AB, Canada 

Burns Blaxall, PhD 


Emile Daoud, MD 

Columbus, OH 

Gerasimos Filippatos, MD 

Athens, Greece 

Joan Heller-Brown, PhD 

San Diego, CA 

6 

Barry Bleske, PharmD 

Ann Arbor, MI 

Christopher DeFilippi, MD 

Baltimore, MD 

Shannon Finks, PharmD 

Memphis, TN 

Adrian Hernandez, MD 

Durham, NC 

7



Ray Hershberger, MD 

Columbus, OH 

Andrew C. Kao, MD 

Kansas City, MO 

Phillip Levy, MD, MPH 

Detroit, MI 

Shawn Merhaut, MSN, ACNP-BC 

Akron, OH 

Sean Pinney, MD 

New York, NY 

Markus P. Schlaich, MD 

Erlangen, Germany 

Anne L. Taylor, MD 

New York, NY 

Clyde W. Yancy, MD 

Chicago, IL 

J. Thomas Heywood, MD 

La Jolla, CA 

Navin Kapur, MD 

Boston, MA 

Wayne Levy, MD 

Seattle, WA 

Joseph M. Metzger, PhD 


Athena Poppas, MD 

Providence, RI 

Douglas Schocken, MD 

Durham, NC 

David Taylor, MD 

Cleveland, OH 

Edward TH Yeh, MD 

Houston, TX 

Joseph Hill, MD, PhD 

Dallas, TX 

David A. Kass, MD 

Baltimore, MD 

Gergory D. Lewis, MD 

Boston, MA 

Theodore E. Meyer, MD 

Worcester, MA 

Kenneth D. Poss, PhD 

Durham, NC 

Marc Semigran, MD 

Boston, MA 

Ryan J. Tedford, MD 

Baltimore, MD 

Larry H. Young, MD 

New Haven, CT 

Vivian Ho, PhD 

Houston, TX 

Stuart Katz, MD 

New York, NY 

Kelly Ann Light-McGroary, MD 

Iowa City, IA 

Jeffery D. Molkentin , PhD 


Jill Rafael-Fortney, PhD 

Columbus, OH 

Mark V. Sherrid, MD 

New York, NY 

John R. Teerlink, MD 

San Francisco, CA 

Ellen Zane 

Boston, MA 

Douglas A. Horstmanshof, MD 


Daniel P. Kelly, MD 

Orlando, FL 

JoAnn Lindenfeld, MD 

Denver, CO 

David Morales, MD 


Kismet Rasmusson, MS, FNP-BC 

Salt Lake City, UT 

Hiroaki Shimokawa 

Sendai, Japan 

Jeffrey J. Teuteberg, MD 

Pittsburgh, PA 

Kathleen Zarling, MS, RN, CNS 

Rochester, MN 

Steven R. Houser, PhD 


Rami Khayat, MD 

Chicago, IL 

Mark S. Link, MD 

Boston, MA 

Javid J. Moslehi, MD 

Boston, MA 

Margaret M. Redfield, MD 

Rochester, MN 

Sandra Sieck, RN 

Mobile, AL 

David Thomas, MD 


Michael Zile, MD 

Charleston, SC 

Andrew Howarth, MD 

Alberta, ON, Canada 

Michael Kiernan, MD 

Boston, MA 

Peter Liu, MD 

Ottawa, ON, Canada 

Jean Nappi, PharmD 

Charleston, SC 

Nita Reigle, MSN, ACNP 

Charlottesville, VA 

Jagmeet Singh, MD 

Boston, MA 

Thomas Thum, MD, PhD 

Hannover, Germany 

Jill Howie-Esquivel, PhD, NP 

San Francisco, CA 

James Kirkpatrick, MD 


Qinghang Liu, MD 

Seattle, WA 

Karl Nelson, RN, MBA 


Jill L. Repoley, MSN, CRNP 

Lancaster, PA 

Nancy Skinner, RN, CCM 

Whitwell, TN 

Robin Trupp, PhD, RN, ACNP-BC 

Durham, NC 

Sharon Hunt, MD 

Stanford, CA 

Kirkwood Adams, MD 


John Lopshire, MD 

Indianapolis, IN 

John B. O’Connell, MD 

Atlanta, GA 

Michael W. Rich, MD 

St. Louis, MO 

Scott Solomon, MD 

Boston, MA 

James Udelson, MD 

Boston, MA 

Dennis Irwin, MD 

Minnetonka, MN 

Jon Kobashigawa, MD 


Pranav Loyalka, MD 

Houston, TX 

Christopher O’Connor, MD 

Durham, NC 

Barbara Riegel, PhD 


Prem Soman, MD, PhD 


Eva van Rooij, PhD 

Utrecht, the Netherlands 

Mitsuaki Isobe, MD 

Tokyo, Japan 

Walter J. Koch, PhD 


Robb MacLellan, MD 


Brian O’Rourke, PhD 

Baltimore, MD 

Jeffrey Robbins, PhD 


Paul Sorajja, MD 

Rochester, MN 

Kenneth Walsh, PhD 

Boston, MA 

James Januzzi, MD 

Boston, MA 

Robb Kociol, MD 

Boston, MA 

Alan Maisel, MD 

San Diego, CA 

Linda Ordway, RN, MS, ACNP-BC 

Boston, MA 

JoEllen Rodgers, PharmD 


Randall Starling, MD 

Cleveland, OH 

Mary N. Walsh, MD 


Brian E. Jaski, MD 

San Diego, CA 

Alan Kono, MD 

Lebanon, NH 

Douglas Mann, MD 

St. Louis, MO 

Mary Orencole, NP 

Boston, MA 

Joseph Rogers, MD 

Durham, NC 

Joseph Stehlik, MD, MPH 


Yibin Wang, PhD 


Shahrokh Javaheri, MD 

Mason, OH 

Marvin A. Konstam, MD 

Boston, MA 

Martin S. Maron, MD 

Boston, MA 

Robert Page, PharmD 

Denver, CO 

Paul Rosenberg, MD 

Durham, NC 

Kenneth Stein, MD 


Lei Wei, PhD 


John Lynn Jefferies, MD, MPH 


Maria Kontaridis, PhD 

Boston, MA 

Paul J. Mather, MD 


Peter S. Pang, MD 

Chicago, IL 

Heather Ross, MD 


Elaine Steinke, PhD, APRN, CNS-B 

Wichita, KS 

Detlef Wencker, MD 

Hartford, CT 

Mariell Jessup, MD 


Rachel Lampert, MD 

New Haven, CT 

Daniel Matlock, MD, MPH 

Denver, CO 

Ayan Patel, MD 

Boston, MA 

Stuart Russell, MD 

Baltimore, MD 

Lynn Warner Stevenson, MD 

Boston, MA 

Linda Wick, RN, MSN, CNP 

Duluth, MN 

Elizabeth A. Jonas, MD 

New Haven, CT 

Ann Laramee, APRN, MS 

Burlington, VT 

Matthew Maurer, MD 

New York, NY 

J. Herbert Patterson, PharmD 


John Ryan, MB, BCh 


William Stevenson, MD 

Boston, MA 

Bruce Wilkoff, MD 

Cleveland, OH 

Karen Joynt, MD 

Boston, MA 

Mark Lawson, MD 

Nashville, TN 

Edwin C. McGee Jr., MD 

Chicago, IL 

Sara Paul, DNP, FNP 

Hickory, NC 

Hani Sabbah, PhD 

Detroit, MI 

Mark Sussman, MD 

San Diego, CA 

Robert Willette, PhD 

King of Prussia, PA 

Bodh Jugdutt, MBChB, MSc, MD 

Edmonton, AB, Canada 

Christopher S. Lee, PhD, RN 

Portland, OR 

Elizabeth McNally, MD 

Chicago, IL 

Michael Petty, PhD, RN, CCNS, ACNSBC 


Mitchell Saltzberg, MD 

Newark, DE 

Nancy Sweitzer, MD, PhD 

Madison, WI 

Monte Willis, MD, PhD 


Corrine Y. Jurgens, PhD, RN 

Stony Brook, NY 

Carl V. Leier, MD 

Columbus, OH 

Dennis McNamara, MD 


Kerry Pickworth, PharmD 

Columbus, OH 

William H. Sauer, MD 

Denver, CO 

Keith Swetz, MD 

Rochester, MN 

Suzanne J. Wingate, PhD, CRNP 

Gaithersburg, MD 

Andreas Kalogeropoulos, MD 

Atlanta, GA 

Annarosa Leri, MD 

Boston, MA 

Roxana Mehran, MD 

New York, NY 

Ileana Pina, MD 

New York, NY 

Douglas Sawyer, MD, PhD 

Nashville, TN 

Michelle Tallquist, PhD 

Honolulu, HI 

Joseph Wu, MD, PhD 

Stanford, CA 

8 

9



Program at a Glance 

Sunday-September 22, 2013 

TIME SCIENTIFIC PROGRAM/SATELLITES EXHIBIT HALL OTHER 

8:00 AM Committee 

Meetings 

10:00 AM Clinical 

Satellite: 

Satellite: 

12:00 PM 

12:30 PM 

fundamentals 

I: Management 

of acute HF/ 

cardiorenal 

syndrome 

10:00-12:30 

1:00 PM Satellite: Satellite: Satellite: 

3:00 PM 

3:30 PM Excellence in ICCAC-VAD Myocarditis Joint HFSA/ 

4:00 PM 

5:30 PM 

basic science: 

Regeneration of 

the heart 

3:30-6:00 

3:30-6:00 

Symposium 

3:30-6:30 

AHA Session on 

Prevention 

3:30-5:00 

Heart Failure with 

6:00 PM Preserved Ejection 

Fraction 5:00-6:30 

Opening reception 

8:00 PM 

Monday-September 23, 2013 


7:00 AM Satellite: 

Sleep disordered 

breathing 

8:15 AM Opening remarks 

Lifetime 

achievement award 

Satellite: 

Hyponatremia 

Satellite: 

8:30 AM Plenary session: 

Healthcare reform 

9:30 AM 8:30-10:00 

10:00 AM Refreshment break Exhibit hall opens 

10:00 AM 

10:30 AM Guideline session 1: Cardiac 

2: Determining 3: Heart failure 4: Imaging update Hands-on 

10:30-12:00 fibroblasts and readiness for trials: The year in in heart failure workshops 

fibrosis 

discharge in HF review 

10:00-400 

12:00 PM Lunch break 

12:30 PM RAPID-FIRE HT 1: Integrating 

percutaneous circ. 

support into a HF 

program 

1:30 PM 

2:00 PM HFSA/HRS session 

2:00-3:30 

3:30 PM Refreshment break 

4:00 PM Late Breaking 

News 

4:00-5:30 

5: Drugable 

signaling pathways 

that underlie HF 

9: Clinical trials 

with stem cells for 

heart repair 

HT 2: How to 

build a success-ful 

advanced HF team 

6: Promoting 

patient-centered 

care 

10: Quality of life 

in HF: What about 

sex? 

HT 3: How to 

treat AF in the HF 

patient 

7: Heart Failure 

Readmissions: 

Approp. Focus or 

Misguided Efforts? 

11: Heart Failure in 

the Frail Elderly 

HT 4: How to 

manage end-of-life 

care 

8: Heart Failure in 

Cancer Patients and 

Survivors 

12: Non-traditional 

HF biomarkers 

Presenters at 

posters 

12:30-1:30 

Hands-on 

workshops 

10:00-400 

4:30 PM 

5:30 PM 

6:00 PM Satellite: Satellite: Exhibit hall closes 

6:00 PM 

EM interest group 

meeting 

7:00 PM Receptions 

7:30 PM Faculty dinner 

10:00 PM 

Program at a Glance 

Tuesday-September 24, 2013 



Fundamentals II: 

Myocarditis 

7:00-8:15 

Satellite: 

7:15-8:15 

Satellite: 

7:15-8:15 

8:30 AM European 

13: MicroRNAs as 14: Alternative 15: Contemp-orary 16: Cardiac 

HF/HFSA session novel CV disease and OTC medicine Issues in Cardiac amyloidosis 

9:30 AM 8:30-10:00 

targets 

in HF 

Transplantation 

10:00 AM Refreshment break Exhibit hall opens 

10:00 AM 

10:30 AM Case discussion Nursing research 

17: Mitochondria 

10:30-12:00 award 

and heart dis 

12:00 PM Lunch break 

12:30 PM RAPID-FIRE HT 5: How to 

optimize CRT 

therapy 

1:30 PM 

1:45 PM Award presentation 

2:00 PM Hyde Park 

2:00-3:30 

3:30 PM Refreshment break 

4:00 PM Debates 

4:00-5:30 

4:30 PM 

1:30-day 

5:30 PM readmission rate 

2: LVADs 

Industry session 

20: Duchenne 

muscular dystrophy 

CM 

JNC young 

investigator: 

clinical 

HT 6: Teach me 

how to teach back 

18: Nitric oxide 

modulation in left 

HF 

22: Quality of Care 

Issues in LVAD 

Therapy 

JNC young 

investigator: basic 

science 

HT 7: How to 

troubleshoot 

continuous flow 

VADs 

19: Acute HF: Role 

of EMS and the ED 

MOC 

study session II 

HT 8: How to 

pursue a career 

in HF 

MOC 

study session 

Hands-on 

workshops 

10:00-400 

Presenters at 

posters 

12:30-1:30 

Hands-on 

workshops 

10:00-400 

6:00 PM Satellite Satellite Exhibit hall closes 

6:00 PM 

7:00 PM 

7:30 PM Satellite Satellite 

10:00 PM 

Wednesday-September 25, 2013 



Fundamentals III: 

HCM Patient 

7:00-8:15 

Exhibit hall closed 

8:15 AM HFSA business 

meeting 

8:30 AM 23: Role of small 

GTPases in cardiac 

function and failure 

10:00 AM Refreshment break 

10:30 AM 27: Are TRP 

channels drugable 

therapeutic targets 

in HF? 

12:00 PM Adjourn 

24: Percutaneous 

devices for 

advanced HF 

patients 

28: Devicebased 

autonomic 

modulation for HF 

25: Strategies 

to Reduce 

Heart Failure 

Readmissions 

29: Destination 

therapy: Is it worth 

the trip? 

26: Pulmonary 

Hypertension in 


10 

11



Sunday – September 22 

10:00 AM-12:30 PM 

Clinical Fundamentals I: 

Management of Acute Heart Failure 

Moderators: Heather Ross, Toronto, ON, Canada 

William T. Abraham, Columbus, OH 

10:00 Epidemiology Trends and Precipitating Factors 

Mihai Gheorghiade, Chicago, IL 

10:10 Initial Evaluation and Stabilization 

Carl V. Leier, Columbus, OH 

10:25 Hemodynamics of Acute Heart Failure: When is Monitoring 

Appropriate? 

Mark Drazner, Dallas TX 

10:40 Development of Cardiorenal Syndrome 

John Burnett Jr., Rochester, MN 

10:55 Components of Treatment: Diuretics and Vasodilators 

JoAnn Lindenfeld, Denver, CO 

11:10 Questions and Panel Discussion 

Faculty 

11:20 Is There Still a Role for Inotropes and Ultrafiltration? 

Maria Rosa Costanzo, Naperville, IL 

11:35 Discharging the Acute Heart Failure Patient: Nursing 

Considerations 

Linda J. Ordway, Boston, MA 

11:50 Timing of Discharge: What Should We Target? 

Michael Felker, Durham, NC 

12:05 Monitoring Devices and Prevention Strategies 

Philip Adamson, Oklahoma City, OK 


Faculty 

12:30 Adjourn 


10:00 AM-12:00 PM 

Satellites 


1:00- 3:00 PM 

Satellites 


3:30-6:00 PM 

Excellence in Basic Science: Regeneration of the Heart 

Moderators: Robb MacLellan, Los Angeles, CA 

Mark A. Sussman, San Diego, CA 

3:30 Regenerative Capacity of the Heart 

Kenneth Poss, Durham, NC 

4:20 Update on Clinical Trials of Stem Cells Regenerating 

the Human Heart 

Joshua Hare, Miami, FL 

4:45 The Role of the Epicardium in Heart Regeneration 

Eduardo Marban, Los Angeles (Invited) 

5:10 Regulation of Cardiac Myocyte Proliferation in Promoting 

Regeneration 

Robb MacLellan, Los Angeles, CA 

5:35 Novel Signaling Mechanisms Underlying Stem 

Cell Activity in the Heart 

Mark A. Sussman, San Diego, CA 

6:00 Adjourn 


3:30-6:00 PM 

ICCAC-VAD Session 

Moderators: Tonya Elliott, Fairfax, VA 

Michael Petty, Minneapolis, MN 

MCS Care in the Community 

3:30* From a Distance – Collaborative Care Between the Implanting 

Center and the Community Heart Failure Cardiologist/Team 

Karl Nelson, Oklahoma City, OK 

3:50* Whom Are You Calling Incompetent? Maintaining VAD Care 

Competency in Community Hospitals 

Suzanne Chillcott, San Diego, CA 

Where is my 10:00 Patient? Patient Self -Care Issues in MCS 

4:10* Reading the Crystal Ball – Does Demonstrated Self-Care 

Ability Predict Patient Success in the Post LVAD Period? 

Does It Matter? 

Keith Aaronson, Ann Arbor, MI 

4:30* Partnering with the Patient to Achieve Success – Using 

Motivational Interviewing to Engage Adherence 

Kathleen K. Zarling, Rochester, MN 

VADs in Children and Adolescents – 

Addressing Congenital Heart Disease with MCS 

4:50* Bridge to Transplant or Destination Therapy – Is there a better 

strategy 

John Lynn Jefferies, Cincinnati, OH 

5:10* Is There Such a Thing as Too Complex Congenital Heart 

Disease for MCS? 

David Morales, Cincinnati, OH 

*20 minutes presentation, 10 minutes discussion 

Case Studies: 

The Toughest Patients You May Ever See 

5:30 Case #1 

Randy Starling, Cleveland, OH 

5:45 Case #2 

Shauna Andrus, Seattle, WA 

6:00 Adjourn 


3:30-6:30 PM 

Symposium on Myocarditis 

(jointly sponsored with the Myocarditis Foundation) 

Moderator: Monte Willis, Chapel Hill, NC 

3:30 Etiology and Prognosis in Acute Myocarditis: When does 

Cause Matter? 

Leslie T. Cooper, Rochester, MN 

3:45 When Should You Consider Endomyocardial Biopsy? 

Stuart D. Russell, Baltimore, MD 

4:00 Imaging in Myocarditis: When to Choose CMR, PET and 

Echo? 

Andrew Howarth, Calgary, AB, Canada 

4:15 Should Myocarditis Ever Influence VAD or Transplant 

Management? 

Dennis McNamara, Pittsburgh, PA 

4:30 Panel Discussion and Audience Q and A 

Drs. Cooper, Russell, Friedrich, and McNamara 

4:50 Break 

Moderator: Madeleine W. Cunningham, Oklahoma City, OK 

5:00 When Should I Care If My Cardiomyopathy Patient Has Antiheart 

Autoantibodies? 

Roland Jahns, Wurzburg, Germany (Invited) 

5:15 Translational Studies of ST2 and Il33 in Human and Murine 

Models of Myocarditis 

DeLisa Fairweather, Baltimore, MD 

5:30 The Role of Treg and Th17 in Human and Murine Models of 

Myocarditis 

Peter Liu, Ottawa, ON, Canada 

5:45 T Cell Plasticity: Implications for Myocarditis 

Madeleine W. Cunningham, Oklahoma City, OK 

6:00 Bringing It All Together: The International Myocarditis 

Registry and Bio Bank 

Lori Blauwet, Rochester, MN 

Faculty 

6:15 Adjourn 


3:30-5:00 PM 

HFSA/AHA Joint Session: The Prevention of Heart Failure 

Moderators: JoAnn Lindenfeld, Denver, CO 

Javed Butler, Atlanta, GA 

3:50 Mechanisms Underlying the Progression of Heart Failure 

Michael Zile, Charleston, SC 

4:10 Medical Therapy to Prevent Heart Failure 

Lee Goldberg, Philadelphia, PA 

4:30 Preventing Heart Failure: Should We Cast a Wider Net? 

Jay N. Cohn, Minneapolis, MN 

4:50 Panel Discussion 

Faculty 

5:00 Adjourn 


5:00-6:30 PM 

Treatment of Heart Failure with Preserved Ejection 

Fraction: What Will Fill This Unmet Need? 

Moderators: Scott Solomon, Boston, MA 

5:00 What Mechanisms Remain Viable Targets for Effective 

Therapy? 

Michael Zile, Charleston, SC 

5:15 Are Heart Failure Biomarkers Useful in HFpEF? 

Inder Anand, Minneapolis, MN 

5:30 Is There a Role for Neuromodulation and Remote Monitoring? 

William A. Abraham, Columbus, OH 

5:45 What Doesn’t Work and What Might Work: PDE-5 Inhibitors, 

Aldosterone Antagonists, BNP 

Marc Semigran, Boston, MA 

6:00 Challenges in the Design of Future Trials 

Marc Pfeffer, Boston, MA (Invited) 


Faculty 

6:30 Adjourn 


6:30-8:00 PM 

Opening Reception 

3:30 Screening to Detect Individuals at Risk for Heart Failure 

Margaret Redfield, Rochester, MN 

12 13



Monday – September 23 

7:00-8:00 AM 

Satellite Symposium: Sleep Disordered Breathing in Heart Failure: A 

Target for Improved Outcomes 

Satellite Symposium: Hyponatremia in Heart Failure: Unraveling the 

Complexities of Optimum Patient Management 


8:15-8:30 AM 

Opening remarks 

Lifetime achievement award 

David DeNofrio, Boston, MA 

Jeffery Molkentin, Cincinnati, OH 

Robin Trupp, Durham, NC 


8:30-10:00 AM 

Plenary Session: 

The Impact of Healthcare Reform 

Moderators: Joseph A. Hill, Dallas, TX 

Marvin A. Konstam, Boston, MA 

8:30 How Do We Reduce Healthcare Spending (Safely)? 

Michael Chernew, Boston, MA 

9:00 The Affordable Care Act: What It Means to Physicians and 

Hospitals 

Vivian Ho, Houston, TX 

9:30 A CEO Checklist for High Value Healthcare 

Ellen Zane, Boston, MA 

10:00 Adjourn 

Monday, September 23 

10:30 AM-NOON 

Guideline Session: Acute Heart Failure Syndromes: New 

Studies, New Outcomes – Better Guidelines? 

Moderators: Michael Givertz, Boston, MA 

Peter E. Carson, Washington, DC 

10:30 Registry vs RCT: Guideline Lessons from ASCEND-HF 

Padma Kaul, Edmonton, AB, Canada 

10:45 Emerging Evidence for Volume Management: Should the 

Guidelines Change? 

Nancy K. Sweitzer, Madison, WI 

11:00 Emerging Evidence for Vasodilators: Should the Guidelines 

Stay the Same? 

Monica Colvin-Adams, Minneapolis, MN 

11:15 Unfavorable Quality of Life Post- Discharge: Predictions and 

Interventions 

Larry Allen, Denver, CO 

11:30 ACCF/AHA Guideline Update on Acute Heart Failure 

Mariell Jessup, Philadelphia, PA 

11:45 ESC Guideline Update on Acute Heart Failure 

Stefan Anker, Berlin, Germany 


10:30 AM-NOON 

Cardiac Fibroblasts and Fibrosis: New Frontiers from 

Bench to Bedside 

Moderators: Burns Blaxall, Cincinnati, OH 

Nikolaos Frangogiannis 

10:30 Cardiac Fibroblasts in Development and Disease 

Michelle Tallquist, Honolulu, HI 

10:45 Cardiac Fibroblasts: The Janus Myocardial Cell 

Burns C. Blaxall, Cincinnati, OH 

11:00 Fibroblast-Myocyte Communication in the Pathogenesis of 


Invited 

11:15 Fibroblasts and ECM in Cardiac Remodeling 

Nikolaos Frangogiannis, Philadelphia, PA 

11:30 What is the Cardiac Fibroblast? 

Troy Baudino, Bryan, TX 

11:45 Monocyte Origin of the Cardiac Fibroblast 

Mark Entman, Houston, TX 

12:00 Adjourn 


10:30 AM-NOON 

Determining Readiness for Discharge in Heart Failure 

Moderators: Zubin Eapen, Durham, NC 


10:30 Assessing Volume 

J. Thomas Heywood, La Jolla, CA 

10:45 The Role of Biomarkers 

James Januzzi, Boston, MA 

11:00 Functional Assessment Prior to Discharge 

Suzanne J. Wingate, Gaithersburg, MD 

11:15 Identifying Discharge Needs 

Nancy Skinner, Whitwell, TN 

11:30 Clinical Implications: Next Steps 

Zubin Eapen, Durham, NC 


Faculty 

12:00 Adjourn 


10:30 AM-NOON 

Heart Failure Trials: The Year in Review 

Moderators: Christopher O’Connor, Durham, NC 

Douglas Mann, St. Louis, MO 

10:30 RELAX-AHF 

John Teerlink, San Francisco, CA 

10:50 CARRESS-HF 

Bradley A. Bart, Minneapolis, MN 

11:10 MADIT- RIT 

N.A. Mark Estes III, Boston, MA 

11:30 RELAX 

Margaret M. Redfield, Rochester, MN 

11:50 BLOCK-HF 

Anne B. Curtis, Buffalo, NY 


Faculty 

12:30 Adjourn 


10:30-NOON 

Imaging Update in Heart Failure 

Moderators: James Udelson, Boston, MA 

Athena Poppas, Providence, RI 

10:30 Use of Contemporary Echocardiography Techniques 

Ayan Patel, Boston, MA 

10:45 Cardiac MR for Assessing Cardiomyopathies 

Mark A. Lawson, Nashville, TN 

11:00 Is Assessing Viability Still Important After STICH? 

James Udelson, Boston, MA 

11:15 Imaging Molecular Myocardial and Interstitial Targets 

Vasken Dilsizian, Baltimore, MD 

11:30 Cost-effective Imaging Algorithms 

Invited 


Faculty 

12:00 Adjourn 


12:30-1:30 PM 

How To Sessions 

1. How to Integrate Percutaneous Circulatory support into Your Heart 

Failure/LVAD Program 

Navin Kapur, Boston, MA 

Michael Acker, Philadelphia, PA 

Gregory Ewald, St. Louis, MO 

2. How to Build a Successful Advanced HF Team 

Mary N. Walsh, Indianapolis, IN 

David Feldman, Minneapolis, MN 

Eugene Chung, Cincinnati, OH 

Mitchell Saltzberg, Newark, DE 

Cynthia Bither, Washington, DC 

3. How to Treat Atrial Fibrillation in the HF Patient 

Jagmeet P. Singh, Boston, MA 

Emile Daoud, Columbus, OH 

Jill Repoley, Lancaster, PA 

4. How to Manage End-Of-Life Care 

Ann Laramee, Burlington, VT 

Suzanne J. Wingate, Gaithersburg, MD 


12:30-1:30 PM 

Rapid-fire session 

Moderators: John Burnett Jr., Rochester, MN 

Paul J. Hauptman, St. Louis, MO 


12:30-1:30 PM 

Presenters at Posters 

12:00 Adjourn 

14 15




2:00-3:30 PM 


2:00-3:30 PM 


2:00-3:30 PM 


4:00-5:30 PM 

HFSA/HRS Session: Implementing the Best CIED 

Therapy for Your Patient 

Moderators: William H. Sauer, Denver, CO 

Bruce Wilkoff, Cleveland, OH 

2:00 Programming: Mode, Rate, Detection and Therapy 

William H. Sauer, Denver, CO 

2:20 Atrial Fibrillation and PVCs: Identification and Response 

J. Thomas Heywood, La Jolla, CA 

2:40 Poor CRT Response: Now What? 


3:00 Subcutaneous or Transvenous ICD: When, Why and Why Not 

Bruce Wilkoff, Cleveland, OH 


Faculty 

3:30 Adjourn 


2:00-3:30 PM 

Promoting Patient-Centered Care: Challenges to 

Autonomy and Justice in a Technological Era 

Moderators: Larry Allen, Denver, CO 

Keith Swetz, Rochester, MN 

2:00 Legal Foundations of Autonomy and Shared Decision-Making 

James Kirkpatrick, Philadelphia 

2:15 The Science of Shared Decision-Making: Risk Communication, 

Measurement and Outcomes 

Daniel Matlock, Denver, CO 

2:30 What Constitutes a Decision Aid: Design and Testing of Tools 

for Shared Decision-Making 

Mary N Walsh, Indianapolis, IN 

2:45 Implementing Shared Decision-Making in Clinical Practice 

Larry Allen, Denver, CO 

3:00 Panel Discussion / Case Studies 

Keith Swetz, Rochester, MN 

Faculty 

3:30 Adjourn 

Heart Failure Readmissions: Appropriate Focus or 

Misguided Efforts? 

Moderators: Clyde Yancy, MD, Chicago, IL 

Marvin Konstam, Boston, MA 

2:00 Rationale for the Metric: Disparities in Practices and 

Outcomes 

Karen Joynt, Boston, MA 

2:20 Reviewing the Evidence Base: Is It Feasible? 

Adrian Hernandez, Durham, NC 

2:40 Challenging the Metric: Is It in the Patient’s Interest? 

Randall Starling, Cleveland, OH 

3:00 Alternatives to Current Policy 

Steven A. Farmer, Chicago, IL 


Faculty 

3:30 Adjourn 


2:00-3:30 PM 

Clinical Trials with Stem Cells for Heart Repair 

Moderators: Joshua Hare, Baltimore, MD 

Annarosa Leri, Boston, MA 

4:00 New Applications For Cell Therapy: Is Cell Therapy Beneficial 

in Dilated Cardiomyopathy? 

Joshua Hare, Baltimore, MD 

4:15 iPS Cells to Understand Calcium Handling in Timothy 

Syndrome 

Ricardo Dolmetsch, Stanford, CA (Invited) 

4:30 Stem Cell Cardiac Engraftment 

Adre Terzic, Rochester, MN (Invited) 

4:45 Are Off the Shelf Approaches to Cell Therapy Viable: Are Any 

Stem Cells Immunologically Privileged? 

Joseph C. Wu, Stanford, CA 

5:00 Summary Of European Stem Cell Transplantation Experience 

Stefan Janssens, Leuven, Belgium (Invited) 

5:15 Translational Perspective from Animal Models with 

cKit Stem Cells 

Annarosa Leri, Boston, MA 

5:30 Adjourn 

Drugable Signaling Pathways that Underlie Heart Failure 

Heart Failure in Cancer Patients and Survivors 

Moderators: Robert Willette, King of Prussia, PA 

Walter Koch, Philadelphia, PA 

2:00 The Receptor Tyrosine Kinases 

Thomas Force, Philadelphia, PA 

2:15 p38 MAP Kinase as a Pathway in Heart Failure 

Robert Willette, King of Prussia, PA 

2:30 PKCalpha as a Target in Heart Failure 

Qinghang Liu, Seattle, WA 

2:45 Can the MAPKs be Targeted to Treat Heart Failure? 

Yibin Wang, Los Angeles, CA 

3:15 AMPK Activation in Metabolic Conditioning of the Heart 

Larry H. Young, New Haven, CT 

3:30 Adjourn 

Moderators: Alan Kono, Lebanon, NH 

Anecita P. Fadol, Houston, TX 

2:00 Anthracycline-Induced Heart Failure: Mechanisms, 

Prevention, and Treatment 

Edward TH Yeh, Houston, TX 

2:20 Targeted Therapy Induced Heart Failure 

Javid Moslehi, DFCI Boston, MA 

2:40 Imaging in the Evaluation and Early Detection of 

Cardiomyopathy 

Jose Banchs, MD Anderson, Houston, TX 

3:00 Utility of Biomarker Monitoring 

Daniela Cardinale, Milan, Italy 


Faculty 

3:30 Adjourn 


4:00-5:30 PM 

Late Breaking News 

Moderators: Kirkwood Adams, Chapel Hill, NC 

Barry Greenberg, San Diego, CA 

Commentators (4-6): TBD 

16 17




4:00-5:30 PM 

Quality of Life in Heart Failure: What About Sex? 

Moderators: Biykem Bozkurt, Houston, TX 

Linda Wick, Duluth, MN 

4:00 Sex in Chronic Heart Failure 

Stuart Katz, New York, NY 

4:20 Guideline Recommendations 

Biykem Bozkurt, Houston, TX 

4:40 Physical and Psychological Aspects of Sexual Dysfunction 

Elaine Steinke, Wichita, KS 

5:00 Speaking Frankly with Patients and Partners 

Susan Barnason, Lincoln, NE 


Faculty 

5:30 Adjourn 


4:00-5:30 PM 

Heart Failure in the Frail Elderly: Perils and Pitfalls 

Moderators: Michael W. Rich, St. Louis, MO 

Daniel E. Forman, Boston, MA 

4:00 Managing Heart Failure in the Context Of Multiple 

Comorbidities 

Daniel E. Forman, Boston, MA 

4:15 Polypharmacy and Drug Interactions 

Robert L. Page II, Denver, CO 

4:30 Device Therapy in the Very Elderly 

Rachel Lampert, New Haven, CT 

4:45 Management of Heart Failure in Long-Term Care 

Corrine Jurgens, Stony Brook, NY 

5:00 End-Of-Life Care in Elderly Heart Failure Patients 

Nancy K. Sweitzer, Madison, WI 


Faculty 

5:30 Adjourn 


4:00-5:30 PM 

Novel Biomarkers for Heart Failure – Eventual Targets for 

Therapy 

Moderators: Mona Fiuzat, Durham, NC 

Alan Maisel, San Diego, CA 

4:00 Galectin-3 and Prognosis in Heart Failure – 

Christopher deFilippi, Baltimore, MD 

4:15 High Sensitivity Troponin: How Useful Is It? – 

G. Michael Felker, Durham, NC 

4:30 Incorporating ST2 testing into Clinical Practice 

James Januzzi, Boston, MA 

4:45 Renal Injury Markers in Acute HF – 

Alan Maisel, San Diego, CA 

5:00 Circulating microRNA as a HF Biomarker – 


5:15 Questions/Panel Discussion 

Faculty 

5:30 Adjourn 


6:00-7:00 PM 

Satellites 


7:30-9:00 PM 

Satellites 


7:00-10:00 PM 

Program Faculty Reception and Dinner 

TUESDAY 

Tuesday, September 24 

7:00-8:15 AM 

Clinical Fundamentals II: 

Approach to the Hypertrophic Cardiomyopathy Patient 

Moderators: James Udelson, Boston, MA 

Howard Eisen, Philadelphia, PA 

7:00 Clinical Evaluation, Cardiac Imaging and Diagnosis 

Martin S. Maron, Boston, MA 

7:15 Genetic Testing and Family Counseling 

Ray Hershberger, Columbus, OH 

7:30 Optimizing Drug Therapy for HCM 

Mark Sherrid, New York, NY 

7:45 Left Ventricular Outflow Tract Obstruction: Surgical 

Myomectomy vs. Alcohol Septal Ablation 

Paul Sorajja, Rochester, MN 

8:00 Preventing Sudden Cardiac Death in HCM 

William Stevenson, Boston, MA 

8:15 Adjourn 


7:00-8:15 AM 

Satellites 


8:30-10:00 AM 

HFSA - HFA of the ESC - Japanese HF Society 

Joint Session 

Moderators: Mitsuaki Isobe, Tokyo, Japan 


8:30 Diuretic Resistance: How Should We Address It? 


8:45 Increased Occurrence of Heart Failure in the Great East 

Japan Earthquake 

Hiroaki Shimokawa, Sendai, Japan 

9:00 Addressing Anemia in Heart Failure 

Gerasimos Filippatos, Athens, Greece 

9:15 Aging and Heart Failure: Can We Delay Senescence? 


9:30 Implications of Cachexia in Chronic Heart Failure 

Stefan Anker, Berlin, Germany 

9:45 Questions and Answers 

Faculty 


8:30-10:00 AM 

MicroRNAs as Novel Cardiovascular Disease Targets 

Moderator: Eva van Rooij, Utrecht, the Netherlands 

Daniel P. Kelly, Orlando, FL 

8:30 MicroRNAs Regulating Heart Disease 

Da-Zhi Wang, Boston, MA (Invited) 

8:45 Targeting Cardiac MicroRNAs in Heart Failure 

(Invited) 

9:00 MicroRNAs Underlying Epigenetic Stress Regulation in the 

Heart 

Gerald W. Dorn II, St. Louis, MO 

9:15 miRNAs Controlling Nuclear Receptors and Cardiac 

Metabolism 

Daniel P. Kelly, Orlando, FL 

9:30 miRNAs Regulating Cardiac Remodeling 

Thomas Thum, Hannover, Germany 

9:45 Therapeutic Regulation of miRNAs in Heart Disease 

Eva van Rooij, Utrecht, the Netherlands 

10:00 Adjourn 


8:30-10:00 AM 

Alternative and OTC Medicine Conundrum— 

Considerations in Heart Failure 

Moderators: Sheryl Chow, Los Angeles, CA 

Kerry Pickworth, Columbus, OH 

8:30 The Scope of the Problem 

Sheryl Chow, Los Angeles, CA 

8:35 Over the Counter Medications to Avoid 

JoEllen Rodgers, Chapel Hill, NC 

8:55 Alternative Medications to Avoid 

Barry Bleske, Ann Arbor, MI 

9:15 Recommendations to Reduce the Problem 

Jean Nappi, Charleston, SC 

9:35 The Role in Medication Reconciliation 

Robert L. Page II, Denver, CO 

9:55 Questions and Answers 

Faculty 

10:00 Adjourn 

10:00 Adjourn 

18 19




8:30-10:00 AM 

Contemporary Issues in Cardiac Transplantation 

Moderators: Sharon Hunt, Stanford, CA 

Michael Acker, Philadelphia, PA 

8:30 Calcineurin Free Immunosuppression In Renal Dysfunction 

David Taylor, Cleveland, OH 

8:45 Management Strategies for Allograft Vasculopathy 

James Fang, Cleveland, OH 

9:00 Managing Comorbid Conditions: How Old Is Too Old? 

Josef Stehlik, Salt Lake City, UT 

9:15 Desensitization Strategies for Allosensitized Candidates 

Jon Kobashigawa, Los Angeles, CA 

9:30 Approach to Diagnosis and Treatment of Antibody Mediated 

Rejection 

Michael Kiernan, Boston, MA 


Faculty 

10:00 Adjourn 


8:30-10:00 AM 

Cardiac Amyloidosis 

Moderators: Stuart Katz, New York, NY 

8:30 Protein Quality Control in the Pathogenesis Of 

Cardiomyopathy 

Jeffrey Robbins, Cincinnati, OH 

8:45 Molecular Mechanisms of Cardiomyocyte Dysfunction in AL 

Amyloidosis 

Frederica del Monte, Boston, MA 

9:00 Advances in Cardiac Amyloidosis Imaging 

Sharmila Dorbala, Boston, MA 

9:15 TTR Amyloidosis: Advances in Diagnosis Treatment 

Mathew Maurer, New York, NY 

9:30 AL Amyloidosis: Advances in Diagnosis and Treatment 

Rodney H. Falk, Boston, MA (Invited) 


Faculty 

10:00 Adjourn 


10:30-NOON 

Case Discussion 

Moderators: James Fang, Cleveland, OH 

Nancy Albert, Cleveland, OH 

Panel Discussants: 

John Chin, Sacramento, CA 

Herb Patterson, Chapel Hill, NC 

Nita Reigle, Charlottesville, VA 

Jalal Ghali, Detroit, MI 

Andrew C. Kao, Kansas City, MO 


10:30-NOON 

Nursing Research Award 

Moderators: Christopher S. Lee, Portland, OR 

Barbara Riegel, Philadelphia, PA 


10:30-NOON 

JNC Young Investigator Award: Clinical 

Moderators: Jay N. Cohn, Minneapolis, MN 

Paul J. Mather, Philadelphia, PA 


10:30-NOON 

JNC Young Investigator Award: Basic Science 

Moderators: Michael Zile, Charleston, SC 

Hani Sabbah, Detroit, MI 


10:30-NOON 

Mitochondria and Heart Disease 

Moderators: Gerald W. Dorn II, St. Louis, MO 

Asa Gustafsson, San Diego, CA 

10:30 Mitochondrial Permeability Transition Pore- Dependent Cell 

Death 

Chris Baines, Columbia, MO 

10:45 Impaired Mitochondrial Quality Control in the Failing Heart 

Asa Gustafsson, San Diego, CA 

11:00 Mitochondrial Fission and Fusion in Regulation of Cardiac 

Homeostasis 

Invited 

11:15 Novel Regulation/Formation of the Mitochondrial Permeability 

Pore 

Elizabeth A. Jonas, New Haven, CT 

11:30 Calcium Regulation by the Uniporter 

Vasi K Mootha, Boston, MA (Invited) 

11:45 Molecular Evidence for the Preconditioning Mitochondrial 

K-ATP Channel 

Brian O’Rourke, Baltimore, MD 

12:00 Adjourn 


12:30- 1:30 PM 

Rapid-fire Session 

Moderators: Douglas Mann, St Louis, MO 

Wayne Levy, Seattle, WA 


12:30- 1:30 PM 

Presenters at Posters 

20 21




2:00 PM-3:30 PM 


2:00 PM- 3:30 PM 


2:00 PM- 3:30 PM 


4:00-5:30 PM 

Hyde Park 

Moderators: Paul Hauptman, St. Louis, MO 

Douglas Schocken, Durham, NC 


2:00 PM-3:30 PM 

Industry Session: How Can We Improve the Heart Failure 

Device Approval Process? 

Moderators: Barry H. Greenberg, San Diego, CA 

Clyde W. Yancy, Chicago, IL 

2:00 Alternatives to the Control Group in Device Trials 

William T. Abraham, Columbus, OH 

2:15 Can We Achieve a More Global Device Approval Process? 

Ileana Piña, New York, NY 

2:30 Post-approval and Registry Studies: How Valuable Are They? 

Roxana Mehran, New York, NY 

2:45 Comparative Effectiveness Studies 

Invited 


Drs. Abraham and Mehran 

Kenneth Stein, Minneapolis, MN 

3:30 Adjourn 


2:00 PM- 3:30 PM 

Nitric Oxide Modulation in Left Heart Failure and 

Translation into Patients 

Moderators: Anne L Taylor, New York, NY 

David Kass, Baltimore, MD 

2:00 NO Signaling in Normal Myocardium 

David Kass, Baltimore, MD 

2:15 NO Dysregulation in Heart Failure 

Bodh Jugdutt, Edmonton, AB, Canada 

2:30 Oxidant Stress and NO Signaling in Heart Failure 

Joshua Hare, Miami, FL 

2:45 Nitrates and NO 

Javed Butler, Atlanta, GA 

3:00 Soluble Guanylyl Cyclase Stimulants and Activators 

John Burnett Jr., Rochester, MN 


Faculty 

3:30 Adjourn 

Acute Heart Failure: Role of Pre-Hospital Care and the 

Emergency Department 

Moderators: Shawn M. Merhaut, Akron, OH 

Peter Pang, Chicago, IL 

2:00 Heart Failure Treatment Begins in the Field 

Gregory J. Fermann, Cincinnati, OH 

2:15 Acute Treatment: Hours 0-12 

Phillip Levy, Detroit, MI 

2:30 Risk Stratification: Who Goes Where and Why? 

Sean Collins, Nashville, TN 

2:45 Observation Medicine and Alternative Sites of Treatment 

Sandra Sieck, Mobile, AL 

3:00 Clinical Implications: Next Steps 

Shawn M. Merhaut, Akron, OH 


Faculty 

3:30 Adjourn 

MOC Study Session I 

Ileana Pina, New York, NY 



4:00-5:30 PM 

Debates 

Moderators: Stephen Gottlieb, Baltimore, MD 

The 30-Day Readmission Rate is an Appropriate Performance Measure for 

Evaluating Heart Failure Quality of Care 

4:00 Pro: Gregg Fonarow, Los Angeles, CA 

4:15 Con: Lynne Warner Stevenson, Boston, MA 

4:30 Questions from Moderators 

Destination LVAD Implantation Should Be Performed Only By 

TransplantCenters 

4:45 Pro: Dennis Irwin, Minnetonka, MN 

5:00 Con: John B. O’Connell, Atlanta, GA 

5:15 Questions from Moderators 

5:30 Adjourn 


4:00-5:30 PM 

Duchenne Muscular Dystrophy Cardiomyopathy: 

Emerging Therapies and Technologies 

Moderators: Daniel J. Garry, Minneapolis, MN 

Elizabeth McNally, Chicago, IL 

4:00 A Neuromuscular Cardiomyopathy Consortium and Therapies 

for Duchenne Muscular Dystrophy 

Daniel J. Garry, Minneapolis, MN 

4:15 DMD Cardiomyopathy: Molecular Mechanisms and 

Experimental Therapeutics 

Joseph Metzger, Minneapolis, MN 

4:30 Multidisciplinary Approaches to Managing Cardiomyopathy in 

Duchenne Muscular Dystrophy 

Elizabeth McNally, Chicago, IL 

4:45 Small-Molecule Activators of SERCA for Treating Heart 

Failure and Duchenne Muscular Dystrophy 

David D. Thomas, Minneapolis, MN 

5:00 Mouse Modeling of Cardiomyopathy in Duchenne MD and 

Suggestive Treatment strategies 

Jill A. Rafael-Fortney, Columbus, OH 


Faculty 

5:30 Adjourn 

A Breath of Fresh Air: Central Sleep Apnea 

Moderators: Sara Paul, Hickory, NC 


4:00 Consequences of CSA 

Nancy Redeker, New Haven, CT 

4:20 Detection and Diagnosis 

Rami Khayat, Chicago, IL 

4:40 Treatment of CSA 

Shahrokh Javaheri, Mason, OH 

5:00 Making It Work: Cases and Clinical Pearls 

Sara Paul, Hickory, NC 


Faculty 

5:30 Adjourn 


4:00-5:30 PM 

Quality of Care Issues in LVAD Therapy 

Moderators: Gregory Ewald, St. Louis, MO 

Edwin McGee, Chicago, IL 

4:00 Key Components of a Quality LVAD Program 


4:15 Hospital Readmissions for LVAD Patients: Can We Stop the 

Bleeding? 

Stuart Russell, Baltimore, MD 

4:30 LVAD Therapy in the Elderly: Are We Providing Quality 

Outcomes? 

Brian Jaski, San Diego, CA 

4:45 Collaborative Approaches to LVAD Infections: Joint ID/Wound 

Care and LVAD clinics 

Michael Kiernan, Boston, MA 

5:00 Importance of Palliative Care in the LVAD Patient 

Mahazarin Ginwalla, Cleveland, OH 


Faculty 

5:30 Adjourn 


4:00-5:30 PM 

MOC Study Session II 

Illeana Pina, New York, NY 



6:00-7:00 PM 

Satellites 


7:30-9:00 PM 

Satellites 

22 23



WEDNESDAY 

Wednesday, September 25 

7:00-8:15 AM 

Clinical Fundamentals III: 

The Pregnant Patient with Heart Failure 

Moderators: Sharon Hunt, Stanford, CA 

Uri Elkayam, Los Angeles, CA 

7:00 Pathophysiology and Patient Identification 

Uri Elkayam, Los Angeles, CA 

7:15 Heart Failure Treatment Strategies and New Potential Targets 

Monica Colvin-Adams, Minneapolis MN 

7:30 Prognosis and Recommendation for Future Pregnancy 

Kismet Rasmusson, Salt Lake City, UT 

7:45 Heart Failure Drugs in Pregnancy: What is Safe? 

Shannon Finks, Memphis, TN 

8:00 Insights from the Peripartum Cardiomyopathy Network 

Dennis McNamara, Pittsburgh, PA 

8:15 Adjourn 


8:15-8:30 AM 

HFSA Business Meeting 


8:30-10:00 AM 

The Role of Small GTPases in Cardiac Function and 

Failure 

Moderators: Jeffery D. Molkentin, Cincinnati, OH 

Maria Kontaridis, Boston, MA 

8:30 Rho Kinase as a Therapeutic Target in Cardiovascular Disease 

Lei Wei, Indianapolis, IN 

8:45 Rac-Induced Left Ventricular Dilation in Thyroxin-Treated 

ZmRacD Transgenic Mice: Role of Cardiomyocyte Apoptosis 

and Myocardial Fibrosis 

Hamdy H. Hassanain, Columbus, OH (Invited) 

9:00 GTPase Regulation of the Cardiac Cytoskeleton 

Frank L. Conlon, Chapel Hill, NC (Invited) 

9:15 RhoA Protects the Mouse Heart Against Ischemia/Reperfusion 

Injury 

Joan Heller-Brown, San Diego, CA 

9:30 RhoA Protects Against Pressure-Overload Induced Heart 

Failure but Induces a Pathological Response to Accelerate 

Cardiac Fibrosis 

Maria Kontaridis, Boston, MA 


8:30-10:00 AM 

Percutaneous Devices For Advanced Heart Failure 

Populations 

Moderators: Navin Kapur, Boston, MA 

Jeffrey Teuteberg, Pittsburgh, PA 

8:30 Axial Flow Catheters: Past, Present and Future 


8:45 Centrifugal Pumps for Right Ventricular Support 

Howard Cohen, Philadelphia, PA (Invited) 

9:00 Devices and Patient Selection for Transcatheter Aortic Valve 

Replacement 

Alan Heldman, Miami, FL (Invited) 

9:15 The Role for Extracorporeal Membrane Oxygenation 

Pranav Loyalka MD, Houston, TX 

9:30 Case Presentations and Discussion 


Jeffrey Teuteberg, Pittsburgh, PA 

Faculty 

10:00 Adjourn 


8:30-10:00 AM 

Strategies to Reduce Heart Failure Readmissions 

Moderators: Theodore E. Meyer, Worcester, MA 

Mary N Walsh, Indianapolis, IN 

8:30 Predictors of Rehospitalization and What Can Be Done To 

Counter Them 

Michael Dickinson, Grand Rapids, MI 

8:45 Transitional Care: Where to See Them After Discharge 

Robb Kociol, Boston, MA 

9:00 Remote Monitoring: Does One Size Fit All? 


9:15 Stumble But Don’t Fall: Use of the HF Observation Unit to 

Prevent Readmission 


9:30 Do They Come to the Hospital to Die? Advanced Care 

Planning and Alternatives to Hospitalization 

KellyAnn Light-McGroary, Iowa City, IA 


Faculty 

10:00 Adjourn 


8:30-10:00 AM 

Pulmonary Hypertension in Heart Failure 

Moderators: James Fang, Cleveland, OH 

Andreas Kalogeropoulos, Atlanta, GA 

8:30 Evaluating Left Heart Disease in Pulmonary Hypertension 

John Ryan, Salt Lake City, UT 

8:45 Effects on Right Ventricular Function 

Ryan Tedford, Baltimore, MD 

9:00 Implications of Pulmonary Hypertension Secondary to HFpEF 

Barry A. Borlaug, Rochester, MN 

9:15 Risk Stratification for Advanced HF Therapies: 

How Much is Too Much? 

Sean Pinney, New York, NY 

9:30 Treatment Strategies: Current and Future 

Gregory Lewis, Boston, MA 


Faculty 

10:00 Adjourn 


10:30 AM-NOON 

Are TRP Channels Drugable Therapeutic Targets in 

Heart Failure? 

Moderators: Steven R. Houser, Philadelphia, PA 

Paul Rosenberg, Durham, NC 

10:30 Overview of SOCE and TRPC in Cardiac Muscle 

Paul Rosenberg, Durham, NC 

10:45 PDE5 and TRPC6 Channel Regulation in the Heart 

David A. Kass, Baltimore, MD 

11:00 Development of TRP Inhibitors and Application to the CV 

System 

David J. Beech, UK 

11:15 Stim1 in Cardiac Failure 

Joseph Hill, Dallas, TX 

11:30 Dominant Negative TRPC Channels Block Cardiac 

Hypertrophy 

Steven R. Houser, Philadelphia, PA 

11:45 TRP Channels in Cardiac Arrhythmia 

Invited 

12:00 Adjourn 


10:30 AM-NOON 

Device-Based Autonomic Modulation for Heart Failure: 

the Next Frontier? 

Moderators: Michael Bristow, Aurora, CO 


10:30 The Cardiac Autonomic Nervous System: A Primer 


10:50 Vagal Nerve Stimulation and Reverse Remodeling: Is There 

Hope? 

Hani N. Sabbah, Detroit MI 

11:10 Spinal Cord Stimulation and Heart Failure: Where Do We 

Stand? 

John Lopshire, Indianapolis, IN 

11:30 Renal Nerve Denervation in the Heart Failure Patient 

Markus P. Schlaich, Erlangen, Germany 


Faculty 

12:00 Adjourn 


10:30 AM-NOON 

Destination LVAD Therapy: Is It Worth the Trip? 

Moderators: Mitchell Saltzberg, Newark, DE 

Keith Aaronson, Ann Arbor, MI 

10:30 Tough Discussions about the Risks and Benefits of Destination 

Therapy 

Joseph Rogers, Durham, NC 

10:45 Quality of Life for DT LVAD Patients 

Kathleen Grady, Chicago, IL 

11:00 Burden on the Family: Caregiver Frailty 


11:15 Falls, Infections and Failure to Thrive: Now What? 

Cynthia Bither, Washington, DC 

11:30 Is Heart Transplant the Bailout Solution? 

Shelley Hall, Dallas, TX 

11:45 Panel Discussion / Case Studies 


12:00 Adjourn 

10:00 Adjourn 

24 25

MEETING REGISTRATION FORM 

2013 Membership application 

Phone: (301) 718-4800 

Fax: (301) 968-2431 

Email info@hfsa.org 

17th Annual Scientific Meeting: September 22-25, 2013 

The Peabody Orlando, Orlando, Florida 

Register Online: at www.hfsa.org (Annual Scientific Meeting.) 

Participant: Please type or print clearly. ALL information requested is required. Incomplete forms will not be processed. Payment in full must 

accompany registration. Only one registrant per form. Please make photocopies of this form for additional registrants. 

Note: To take advantage of the membership registration rate for the 

16th Annual Scientific Meeting (September 22-25, 2012, Orlando, FL) 

individuals must have paid 2013 dues by June 15, 2013. 

Applicant: Please TYPE or PRINT legibly and complete ALL information requested. 

5425 Wisconsin Avenue Tel: (301) 718-4802 

Suite 600 Fax: (301) 968-2431 

Chevy Chase, MD 20815 

www.hfsa.org 

name (last, first, middle initial): 

degree: 

name (last, first, middle initial): 

degree: 

institution: 

mailing address: 

mailing address: 

city: state / province: zip / postal code: country: 

city: state / province: zip / postal code: country: 

phone: fax: email address: 

email address:* cell phone: phone (other): fax: 

present hospital/university affiliation/firm/corporation: 

*Please enter e-mail address carefully. It will be used for verification of attendance and access to credit certificates. 

Registration Fees: To take advantage of the membership rate for the 17th Annual Scientific 

Meeting individuals must have paid 2013 dues by July 30, 2013. See HFSA web site (www.hfsa.org) 

for 2013 Membership Application. 

Registration Profile: 

Registration form will not be accepted 

without this section completed. 

professional education and training 

(college, graduate or medical school, postgraduate training): dates attended degree 

Members: advance after 7/30/13 code Amount 

MD, DO $625 $725 FM $ 

PhD $495 $595 FP $ 

Clinical Practice: 

Yes 

No 

Nurse/Nurse Practitioner $350 $450 FN $ 

Health Professional* $350 $450 FH $ 

Pharmacist $350 $450 PH $ 

FDA/NIH $275 $375 FG $ 

Trainee/Resident** $165 $265 FT $ 

Nonmembers: advance after 7/30/13 code Amount 

Advanced nonmembers registration fees include 2013 membership dues and a subscription to Journal of Cardiac Failure. 

MD, DO $925 $1025 FM $ 

PhD $695 $820 FP $ 

Nurse/Nurse Practitioner $550 $695 FN $ 

Health Professional* $550 $695 FH $ 

Pharmacist $550 $695 PH $ 

FDA/NIH $475 $535 FG $ 

Trainee/Resident** $240 $375 FT $ 

* dietitian, EMS, nutritionist, OT, PA, PT, policy analyst, physiotherapist, technician/research technician, social worker 

** student, fellow, post-doc (full-time status only, signed verification letter from program director required). Letter may 

be faxed to 301-968-2431 or e-mailed to info@hfsa.org. Letters not received within 30 days of registering will result 

in cancellation of meeting registration. Any penalties will apply. 

Payment: 

(Check all professional 

categories that apply) 

Physician 

Scientist/Researcher PhD 

Scientist/Researcher (non PhD) 

Professor 

Nurse Practitioner 

Nurse 

Pharmacist 

Pharmacologist 

Physician Assistant 

Non-medical 

Practice Setting: 

(Check all professional 

categories that apply) 

Private Practice 

Research 

Academic 

Hospital 

Clinic 

Other Healthcare Organization 

Credit card: If paying by credit card you must register on line at www.hfsa.org. Registration may be paid by American Express, Visa or Mastercard. 

Checks/Money Orders: Complete the application and send with check or money order (in US dollars and from US banks only) payable to: 

Heart Failure Society of America (HFSA), 5425 Wisconsin Ave. Suite 600, Chevy Chase, MD 20815. 

present activity in the field of heart failure: 

list other society memberships: 

check here if you do NOT want your name, address or email to appear on mailing lists rented by 

vendors/third parties 

Membership: Calandar year (Jan – Dec). See web site (www.hfsa.org) for membership benefits. 

$300.00 Full Members: MDs, DOs or equivalent who are in good standing in their respective communities, 

and are actively engaged in heart failure practice or research. 

$200.00 Full members (other): all nonphysicains who are in good standing in their respective communities, 

and are actively engaged in heart failure practice or research. 

$75.00 Trainees: open to individuals enrolled as "full-time" medical students, residents, fellows, undergraduate 

students, and pre- and post-doctoral trainees. A letter of verification, including the end of training date, from the 

training program direct is required with payment of dues for each year trainee membership is requested. 

Previous Member? No Yes 

Payment: Dues may be paid with Visa, MasterCard, American Express, check or money order (drawn 

on US banks only). Checks or money orders are payable to: Heart Failure Society of America. 

check money order american express visa mastercard 

account number: 

name of card holder: 

signature of cardholder: 

expiration date (mm/yy): 

Check the category that best 

describes your profession: 

(Check One) 

Adult Cardiologist 

Pediatric Cardiologist 

CV Surgeon 

ED Physician 

Family/General Practitioner 

Internist 

Hospitalist 

Physician, Other 

Scientist – PhD 

Scientist (non-PhD) 

Pharmacist 

Pharmacologist 

Technician/Research Technician 

Nurse/ Nurse Practitioner 

Physician Assistant 

Non-Medical 

Other Health Professional 

Work Environment: (Check One) 

Academic Institution 

Clinic 

Government 

Hospital 

Industry 

Private Practice 

Other Healthcare Organization 

26 

Refunds: If notice of cancellation is received in writing prior to Friday, August 9, 2013, registration fee will be refunded less a $75 administrative 

charge. Registration cannot be transferred. No refunds will be granted after August 10, 2013. Contact info@hfsa.org. 

None of the payment is deductible as a charitable contribution but may be deductible as an ordinary and necessary business expense. 

27

How-To 

Hands-On 

Team-Based 

New Technologies 

17th Annual Scientific Meeting 

September 22 – 25, 2013 

The Peabody Orlando Hotel 

Orlando, Florida 

Heart Failure Society of America 

5425 Wisconsin Avenue, Suite 600 

Chevy Chase, MD 20815

Download - Heart Failure Society of America

Create successful ePaper yourself

Delete template?

Save as template?